spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

CluePoints Appoints Andy Cooper as New Chief Executive Officer

CluePoints

New CEO brings a combination of experience and drive as CluePoints rapidly scales its RBQM and Data Quality Oversight offerings


 
King of Prussia, PA – December 13, 2022: RBQM leader, CluePoints, has today announced Andy Cooper has been appointed as its new Chief Executive Officer. Cooper succeeds Co-Founder, Francois Torche, who is stepping back as CEO to focus his full attention on the strategic direction of CluePoints’ world-leading product portfolio.



Cooper has more than 24 years of clinical trial industry and software experience at companies including Oracle and Medidata. His most recent role was at Clario (previously known as ERT), where he was General Manager for the eCOA Business Unit. His wealth of experience will be fundamental in further accelerating the growth and scale-up of the company.

Patrick Hughes, Co-Founder and Chief Commercial Officer at CluePoints, stated: “One of the things that makes CluePoints extraordinary is the culture we have created. Andy is well suited to take the company forward because he understands what makes the business special through our outstanding workforce and the huge opportunities we have for growth. We are the clear market leader in a fast-growing space with an ever-growing community of customers and partners. It is great to have somebody with Andy's experience who will come in and support us on that continued journey.”

Andy Cooper reinforced the opportunity: “There is huge industry momentum for RBQM, and CluePoints needs to be able to develop products quickly to cope with that extraordinary demand. I am thrilled to have the opportunity to use my experience to help CluePoints continue to grow and flourish.”

Francois Torche, Co-Founder of CluePoints, commented: “CluePoints continues to be as successful as ever, and the company is growing rapidly. This means my time has been increasingly divided between defining the future product strategy and running the company as CEO. My passion is to drive innovation and product development. Therefore, I have decided to step back as CEO to focus my full attention and energy on the strategic direction of our world-leading product portfolio. I am delighted that we have secured Andy as the new CEO for CluePoints and am looking forward to working with him to fulfill the huge ambition we have for the business.”
phone 010 778910
email marc.buyse@cluepoints.com
web www.cluepoints.com
email Axis Parc, rue Emile Francqui 1, 1435 Mont Saint Guibert, Belgium
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Nelipak Healthcare Packaging to establish new U.S. flexible packaging facility


More info >>


White Papers

The Promise and Challenge of Adaptive Design in Oncology Trials

Medpace

Clinical oncology trials are more complex and time consuming than those in any other therapeutic area and failure rates are frustratingly high. Given the urgent need for new oncologic therapies, sponsors are eager to find more effective ways to conduct clinical research. Incorporating adaptive design methodologies into clinical trials can reduce costs and enhance efficiency while maintaining trial integrity. They can also reduce the number of patients on placebo and sub-therapeutic doses. In light of this promise, regulatory bodies have created guidelines supportive of adaptive design.
More info >>

Industry Events

The Pharmaceutical Manufacturing and Packaging Congress 2023 (PHARMAP 2023)

12-13 June 2023, Hilton Geneva Hotel & Conference Centre, Geneva, Switzerland

The Pharmaceutical Manufacturing and Packaging Congress 2023 (PHARMAP 2023) gathers top-level management from pharmaceutical companies of manufacturing, primary and secondary packaging, purchasing, and supply chain and procurement sectors, CMOs and CDMOs leaders, heads from government and institution on 12-13, June, 2023 in Geneva, Switzerland.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement